ArticleInternational ophthalmology2025
Autologous platelet gel as adjunctive therapy for severe corneal ulcers: a pilot study.
Article in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Platelets in Dry Eye Disease: A Narrative Review of Biological Mechanisms and Therapeutic Applications Derived from Platelets.Life (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo explore the clinical feasibility and potential efficacy of a novel autologous platelet gel (APG) formulation-combining platelet-rich plasma (PRP) and autologous thrombin serum (ATS)-for the treatment of severe corneal ulcers with persistent epithelial defects refractory to conventional medical therapies.
methodsThis pilot exploratory study describes a prospective case series of 10 patients (mean age 60 years) presenting with nonhealing corneal ulcers of various etiologies. All patients received APG applied as a single overlay or plug under a bandage contact lens, along with supportive therapy (lubricants, antibiotics, mydriatics, and PRP eye drops). Outcome measures included epithelial healing time, corrected distance visual acuity (CDVA), and AS-OCT imaging. Descriptive analysis was used due to the small sample size.
resultsComplete epithelial healing was observed in all cases within a mean of 10 days (range 7-22 days). One patient required a repeat application due to incomplete healing after the initial procedure. CDVA improved from 0.034 ± 0.05 to 0.216 ± 0.4 LogMAR. No adverse events or ulcer recurrence were reported during a mean follow-up of 8 months (range 2-14 months).
conclusionThis preliminary case series suggests that APG may represent a potential adjunctive therapy for promoting corneal healing in severe, treatment-resistant ulcers. However, due to the small sample size, heterogeneity of etiologies, lack of a control group, and variable follow-up, the evidence should be regarded as exploratory and hypothesis-generating. Larger, stratified, and controlled clinical trials are warranted to confirm safety and effectiveness relative to established therapies.
Indexed as
Identifiers
40986200What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.